Selling, General, and Administrative Costs: Johnson & Johnson vs Blueprint Medicines Corporation

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This chart compares the SG&A expenses of two industry players: Johnson & Johnson and Blueprint Medicines Corporation, from 2014 to 2023.

Johnson & Johnson, a titan in the healthcare sector, consistently reported SG&A expenses around $20 billion annually, showcasing its vast operational scale. In contrast, Blueprint Medicines, a burgeoning biotech firm, saw its SG&A expenses grow from $7.9 million in 2014 to nearly $295 million in 2023, reflecting a staggering 3,600% increase. This growth underscores Blueprint's aggressive expansion and investment in its operations.

While Johnson & Johnson's expenses remained relatively stable, Blueprint's rapid increase highlights the dynamic nature of emerging biotech companies. This comparison offers a fascinating glimpse into how established giants and innovative newcomers navigate financial strategies in the competitive pharmaceutical landscape.